^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    apraglutide (FE 203799)

    i
    Other names: TA 799, FE 203799, FE203799, TA799, FE-203799, TA-799
    Associations

    News

    Trials
    Company:
    Asahi Kasei, Ironwood Pharma
    Drug class:
    GLP-2 receptor agonist
    Associations

    News

    Trials
    1year
    STARGAZE: Proof-of-concept Trial of Apraglutide in GVHD (clinicaltrials.gov)
    P2, N=31, Terminated, VectivBio AG | Trial completion date: Aug 2025 --> Dec 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2025 --> Dec 2024; Company decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    apraglutide (FE 203799)
    over1year
    Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, GlyPharma Therapeutics | Phase classification: P1b/2a --> P1/2
    Phase classification
    |
    CD34 (CD34 molecule)
    |
    melphalan • apraglutide (FE 203799)
    almost2years
    STARS: Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF (clinicaltrials.gov)
    P3, N=164, Completed, VectivBio AG | Active, not recruiting --> Completed
    Trial completion
    |
    apraglutide (FE 203799)
    2years
    Proof-of-concept Trial of Apraglutide in GVHD (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, VectivBio AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    apraglutide (FE 203799)
    2years
    STARS extend: Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. (clinicaltrials.gov)
    P3, N=158, Active, not recruiting, VectivBio AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    apraglutide (FE 203799)
    2years
    Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation (clinicaltrials.gov)
    P1, N=34, Completed, VectivBio AG | Recruiting --> Completed
    Trial completion
    |
    apraglutide (FE 203799)
    4years
    APRAGLUTIDE DOES NOT IMPACT ANTI-TUMOR AND IMMUNOSUPPRESSIVE EFFICACY OF CONDITIONING CHEMOTHERAPY IN MICE (EBMT 2022)
     Pre- and concomitant apraglutide did not impair the efficacy of cytarabine in destroying human leukemia cells in vivo. Moreover, combination with apraglutide had no negative impact on cytarabine- or melphalan-induced immunosuppression. Apraglutide did not negatively impact the antitumor or immunosuppressive effects of cytarabine or melphalan.
    Preclinical
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    cytarabine • melphalan • apraglutide (FE 203799)
    4years
    Apraglutide Does Not Impact Anti-Tumor and Immunosuppressive Efficacy of Conditioning Chemotherapy in Mice (TCT-ASTCT-CIBMTR 2022)
    Pre- and concomitant apraglutide did not impair the efficacy of cytarabine in destroying human leukemia cells in vivo. Moreover, combination with apraglutide had no negative impact on cytarabine- or melphalan-induced immunosuppression. Apraglutide did not negatively impact the antitumor or immunosuppressive effects of cytarabine or melphalan.
    Preclinical
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    cytarabine • melphalan • apraglutide (FE 203799)